NASDAQ:SNGX Soligenix (SNGX) Stock Forecast, Price & News $0.53 +0.03 (+5.58%) (As of 09/22/2023 08:52 PM ET) Add Compare Share Share Today's Range$0.50▼$0.5350-Day Range$0.44▼$0.6952-Week Range$0.42▼$10.93Volume45,300 shsAverage Volume372,408 shsMarket Capitalization$4.30 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Soligenix MarketRank™ ForecastAnalyst Rating0.00 Rating ScoreUpside/Downside466.0% Upside$3.00 Price TargetShort InterestHealthy0.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.56) to ($1.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.55 out of 5 stars 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Soligenix has a forecasted upside of 466.0% from its current price of $0.53.Amount of Analyst CoverageSoligenix has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.25% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently decreased by 90.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoligenix does not currently pay a dividend.Dividend GrowthSoligenix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNGX. Previous Next 2.9 News and Social Media Coverage News SentimentSoligenix has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Soligenix this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SNGX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows3 people have added Soligenix to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soligenix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.36% of the stock of Soligenix is held by insiders.Percentage Held by InstitutionsOnly 17.80% of the stock of Soligenix is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Soligenix are expected to decrease in the coming year, from ($1.56) to ($1.74) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Soligenix (NASDAQ:SNGX) StockSoligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Read More SNGX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNGX Stock News HeadlinesSeptember 22, 2023 | prnewswire.comSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by StockholdersAugust 24, 2023 | finance.yahoo.comSNGX: HyBryte™ Expanded Treatment Trial UnderwaySeptember 25, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 21, 2023 | finanznachrichten.deSoligenix, Inc.: Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial ResultsAugust 21, 2023 | msn.comSoligenix GAAP EPS of -$0.22 beats by $0.16, revenue of $0.2M in-lineAugust 21, 2023 | finance.yahoo.comSoligenix Announces Recent Accomplishments And Second Quarter 2023 Financial ResultsAugust 2, 2023 | finance.yahoo.comSNGX - Soligenix, Inc.July 19, 2023 | finance.yahoo.comSNGX: Expanding SGX302 Phase 2a Study in Psoriasis…September 25, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.June 29, 2023 | finance.yahoo.comSoligenix, Inc. CEO is Featured in an Interview with SmallCaps DailyJune 2, 2023 | finanznachrichten.deSoligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money ReportJune 2, 2023 | finance.yahoo.comSoligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)May 30, 2023 | finance.yahoo.comSNGX: Positive Results for Compatibility Study of HyBryte in CTCLMay 16, 2023 | finanznachrichten.deSoligenix, Inc.: Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial ResultsMay 16, 2023 | finance.yahoo.comSoligenix Announces European Patent Grant for Use of Dusquetide in Oral MucositisMay 15, 2023 | finance.yahoo.comSoligenix Announces Recent Accomplishments And First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comSoligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaMay 9, 2023 | finance.yahoo.comSoligenix Announces Closing of $8.5 Million Public OfferingMay 5, 2023 | finance.yahoo.comSoligenix Announces Pricing of $8.5 Million Public OfferingMay 4, 2023 | finance.yahoo.comWhy Are Soligenix Shares Trading Higher TodayMay 3, 2023 | finance.yahoo.comSoligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of DirectorsMay 1, 2023 | finance.yahoo.comSoligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's DiseaseApril 24, 2023 | finance.yahoo.comSNGX: Planning for Second Phase 3 Study for HyBryte™ in CTCL…April 24, 2023 | finance.yahoo.comSoligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaApril 14, 2023 | msn.comSoligenix Shares Tumble as FDA Demands More DataApril 14, 2023 | msn.comSoligenix stock sinks as FDA seeks additional positive results for cancer drugApril 14, 2023 | finance.yahoo.comSoligenix Provides Regulatory Update on HyBryte™See More Headlines Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Email Address SNGX Company Calendar Last Earnings8/21/2023Today9/24/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNGX CUSIPN/A CIK812796 Webwww.soligenix.com Phone(609) 538-8200Fax609-452-6467Employees13Year Founded1987Price Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+466.0%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,800,000.00 Net Margins-943.00% Pretax Margin-1,056.62% Return on Equity-3,826.28% Return on Assets-65.21% Debt Debt-to-Equity Ratio0.36 Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual Sales$950,000.00 Price / Sales4.53 Cash FlowN/A Price / Cash FlowN/A Book Value($0.85) per share Price / Book-0.62Miscellaneous Outstanding Shares8,120,000Free Float8,006,000Market Cap$4.30 million OptionableNot Optionable Beta1.67 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Christopher J. Schaber Ph.D. (Age 57)Chairman of Directors, CEO & Pres Comp: $638.13kMr. Jonathan L. Guarino CPA (Age 50)CGMA, Sr. VP, CFO & Corp. Sec. Comp: $304.31kDr. Oreola Donini Ph.D. (Age 51)Sr. VP & Chief Scientific Officer Comp: $336.98kDr. Richard C. Straube M.D. (Age 71)MSc., Sr. VP & Chief Medical Officer Comp: $215.07kKey CompetitorsAptevo TherapeuticsNASDAQ:APVOABVC BioPharmaNASDAQ:ABVCArtelo BiosciencesNASDAQ:ARTLZyVersa TherapeuticsNASDAQ:ZVSAPainReformNASDAQ:PRFXView All CompetitorsInstitutional OwnershipAnson Funds Management LPBought 514,144 shares on 8/14/2023Ownership: 6.332%View All Institutional Transactions SNGX Stock - Frequently Asked Questions What is Soligenix's stock price forecast for 2023? 0 Wall Street research analysts have issued twelve-month price objectives for Soligenix's stock. Their SNGX share price forecasts range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 466.0% from the stock's current price. View analysts price targets for SNGX or view top-rated stocks among Wall Street analysts. How have SNGX shares performed in 2023? Soligenix's stock was trading at $0.4520 at the beginning of 2023. Since then, SNGX stock has increased by 17.3% and is now trading at $0.53. View the best growth stocks for 2023 here. Are investors shorting Soligenix? Soligenix saw a decrease in short interest in August. As of August 31st, there was short interest totaling 24,900 shares, a decrease of 90.3% from the August 15th total of 255,600 shares. Based on an average daily trading volume, of 150,200 shares, the short-interest ratio is currently 0.2 days. Currently, 0.3% of the company's stock are short sold. View Soligenix's Short Interest. When is Soligenix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our SNGX earnings forecast. How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings results on Monday, August, 21st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.32. The biopharmaceutical company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 943.00% and a negative trailing twelve-month return on equity of 3,826.28%. What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM). What is Soligenix's stock symbol? Soligenix trades on the NASDAQ under the ticker symbol "SNGX." Who are Soligenix's major shareholders? Soligenix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Anson Funds Management LP (6.33%). Insiders that own company stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube. View institutional ownership trends. How do I buy shares of Soligenix? Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Soligenix's stock price today? One share of SNGX stock can currently be purchased for approximately $0.53. How much money does Soligenix make? Soligenix (NASDAQ:SNGX) has a market capitalization of $4.30 million and generates $950,000.00 in revenue each year. How can I contact Soligenix? Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The official website for the company is www.soligenix.com. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at ir@soligenix.com, or via fax at 609-452-6467. This page (NASDAQ:SNGX) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.